Stockscreener 앱 받기
16.75
0.36%
0.06
전일 마감가:
$16.69
열려 있는:
$16.66
하루 거래량:
463.51K
Relative Volume:
0.69
시가총액:
$917.60M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-6.69%
1개월 성능:
-7.71%
6개월 성능:
+55.24%
1년 성능:
+40.99%
1일 변동 폭
$16.54
$17.16
1주일 범위
$16.45
$18.05
52주 변동 폭
$7.80
$19.71
Bicara Therapeutics Inc Stock (BCAX) Company Profile
명칭
Bicara Therapeutics Inc
전화
617-468-4219
주소
116 HUNTINGTON AVENUE SUITE 703, BOSTON
BCAX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BCAX
Bicara Therapeutics Inc
|
16.75 | 914.31M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Bicara Therapeutics Inc Stock (BCAX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-08 | 개시 | BTIG Research | Buy |
| 2025-12-18 | 개시 | Mizuho | Neutral |
| 2025-08-19 | 개시 | Piper Sandler | Overweight |
| 2025-05-23 | 업그레이드 | Wells Fargo | Underweight → Equal Weight |
| 2025-04-17 | 개시 | Wells Fargo | Underweight |
| 2025-02-06 | 개시 | Wedbush | Outperform |
| 2024-12-06 | 개시 | H.C. Wainwright | Buy |
| 2024-11-05 | 개시 | Rodman & Renshaw | Buy |
| 2024-10-08 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-10-08 | 개시 | Morgan Stanley | Overweight |
| 2024-10-08 | 개시 | Stifel | Buy |
| 2024-10-08 | 개시 | TD Cowen | Buy |
모두보기
Bicara Therapeutics Inc 주식(BCAX)의 최신 뉴스
BCAX: De-Risked FORTIFI-HN01 Path, Differentiated Ficera Profile, and Solid Cash Runway Underpin Buy Rating and $28 Target - TipRanks
Bicara Therapeutics stock maintains Buy rating at BTIG on clinical progress - Investing.com Nigeria
Analysts Have Conflicting Sentiments on These Healthcare Companies: Bicara Therapeutics Inc. (BCAX), NewAmsterdam Pharma Company (NAMS) and GE Healthcare Technologies Inc (GEHC) - The Globe and Mail
Does Bicara Therapeutics Inc align with a passive investing strategyDividend Hike & Weekly Market Pulse Updates - baoquankhu1.vn
H.C. Wainwright reiterates Buy rating on Bicara Therapeutics stock By Investing.com - Investing.com Nigeria
H.C. Wainwright reiterates Buy rating on Bicara Therapeutics stock - Investing.com
How cyclical is Bicara Therapeutics Inc.’s revenue stream2025 Market Outlook & Daily Growth Stock Investment Tips - bollywoodhelpline.com
Bicara Therapeutics (NASDAQ:BCAX) Given Outperform Rating at Wedbush - Defense World
Growth Report: Will Bicara Therapeutics Inc. stock continue upward momentumJuly 2025 Opening Moves & Weekly Breakout Watchlists - Bộ Nội Vụ
Wedbush Reaffirms Outperform Rating for Bicara Therapeutics (NASDAQ:BCAX) - MarketBeat
Bicara selects optimal dose for head and neck cancer drug in pivotal study - Investing.com Nigeria
Bicara Therapeutics Touts Breakthrough Ficerafusp Data, Picks 1,500 mg Dose for FORTIFY-HNS Trial - MarketBeat
Bicara Therapeutics (NASDAQ:BCAX) Shares Down 7%Time to Sell? - MarketBeat
Bicara Sets Phase 3 Path for Ficerafusp Alfa - TipRanks
Bicara Therapeutics announces phase 3 optimal dose and provides 2026 corporate outlook - marketscreener.com
Bicara Therapeutics Inc Announces Phase 3 Optimal Dose and 2026 Outlook - TradingView — Track All Markets
Bicara Therapeutics Announces Phase 3 Optimal Dose And Provides 2026 Corporate Outlook - TradingView — Track All Markets
Bicara Therapeutics Announces Phase 3 Optimal Dose and Provides 2026 Corporate Outlook - GlobeNewswire
Published on: 2026-01-12 06:24:33 - moha.gov.vn
Bicara Therapeutics (NASDAQ:BCAX) Trading 7.8% Higher – Should You Buy? - Defense World
Is Bicara Therapeutics Inc. stock trading at a premium valuationWeekly Trade Review & Precise Trade Entry Recommendations - ulpravda.ru
BTIG Research Begins Coverage on Bicara Therapeutics (NASDAQ:BCAX) - Defense World
Bicara Therapeutics Inc.Common Stock (NQ: BCAX - FinancialContent
Bicara Therapeutics (NASDAQ:BCAX) Trading Up 7.8%Here's Why - MarketBeat
Bicara Therapeutics (NASDAQ:BCAX) Upgraded to "Strong-Buy" at BTIG Research - MarketBeat
Published on: 2026-01-09 02:43:58 - Улправда
Is Bicara Therapeutics Inc. stock a defensive play in 2025July 2025 Breakouts & Safe Entry Trade Signal Reports - Улправда
Bicara Therapeutics Inc. (BCAX) Stock Analysis: Unveiling an 83.84% Potential Upside in the Biotech Arena - DirectorsTalk Interviews
Upcoming EventsBicara Therapeutics Inc.Common Stock (Nasdaq:BCAX) Detailed Stock Data - FinancialContent
BTIG Initiates Coverage of Bicara Therapeutics (BCAX) with Buy Recommendation - Nasdaq
Los Angeles Daily NewsBicara Therapeutics Inc.Common Stock (Nasdaq:BCAX) Price Chart - FinancialContent
History Review: Can Bicara Therapeutics Inc. stock deliver sustainable ROEMarket Risk Summary & Real-Time Market Sentiment Reports - ulpravda.ru
What hedge fund activity signals for Bicara Therapeutics Inc. stockQuarterly Profit Summary & AI Based Trade Execution Alerts - Улправда
Bicara Therapeutics initiated with a Buy at BTIG - TipRanks
BTIG initiates coverage on Bicara Therapeutics stock with Buy rating By Investing.com - Investing.com South Africa
BTIG Research Initiates Coverage on Bicara Therapeutics With Buy Rating, $28 Price Target - MarketScreener
BTIG initiates coverage on Bicara Therapeutics stock with Buy rating - Investing.com
News | postregister.comBicara Therapeutics Inc.Common Stock (Nasdaq:BCAX) Stock Quote - FinancialContent
Can Bicara Therapeutics Inc. stock rebound after recent weaknessEarnings Date Calendar & Free Grow Wealth With Picks - Улправда
Bicara Therapeutics: How InvestingPro’s overvaluation call led to 39% decline By Investing.com - Investing.com South Africa
Bicara Therapeutics management to meet with Cantor Fitzgerald - MSN
Will Bicara Therapeutics Inc. stock continue dividend increases2026 world cup usa national team group stage playmakers pressing system winner prediction preview - Улправда
Bicara Therapeutics Inc. (NASDAQ:BCAX) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
Bicara Therapeutics Inc. (NASDAQ:BCAX) Receives Consensus Rating of “Hold” from Analysts - Defense World
What Drawdown Risk Means for Long Term Holders of Clean Science and Technology LimitedStock Buyback Announcements & Zero-Cost Stock Research by Professionals - earlytimes.in
Wedbush Initiates Coverage of Bicara Therapeutics (BCAX) with Outperform Recommendation - MSN
Bicara Therapeutics (NASDAQ:BCAX) Trading 3.9% Higher – Here’s Why - Defense World
Aug Chart Watch: What hedge fund activity signals for Bicara Therapeutics Inc stockWeekly Market Outlook & Daily Profit Maximizing Tips - moha.gov.vn
Bicara Therapeutics (NASDAQ:BCAX) Stock Price Up 3.9%Still a Buy? - MarketBeat
Straddle Buy Call Buy Put at same strikeEarnings Call Summaries & Exceptional Return Growth - bollywoodhelpline.com
Hyep Ivan, Bicara Therapeutics CFO, sells $168k in BCAX stock - Investing.com India
Bicara Therapeutics Inc (BCAX) 재무 분석
Bicara Therapeutics Inc (BCAX)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
Bicara Therapeutics Inc 주식 (BCAX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Cohlhepp Ryan | President and COO |
Dec 26 '25 |
Option Exercise |
4.44 |
25,000 |
110,922 |
214,141 |
| Raben David | Chief Medical Officer |
Dec 26 '25 |
Option Exercise |
3.79 |
19,789 |
74,996 |
55,286 |
| Hyep Ivan | Chief Financial Officer |
Dec 22 '25 |
Option Exercise |
3.79 |
9,200 |
34,866 |
154,555 |
| Hyep Ivan | Chief Financial Officer |
Dec 22 '25 |
Sale |
18.31 |
9,200 |
168,492 |
145,355 |
4.73%
0.92%
자본화:
|
볼륨(24시간):